| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Microbiology | 21 | 2020 | 70 | 5.490 |
Why?
|
| Periodicals as Topic | 24 | 2024 | 1465 | 3.160 |
Why?
|
| Microbiological Techniques | 7 | 2019 | 97 | 2.680 |
Why?
|
| Microbial Sensitivity Tests | 15 | 2023 | 1967 | 2.530 |
Why?
|
| Clinical Laboratory Techniques | 8 | 2020 | 747 | 2.310 |
Why?
|
| Editorial Policies | 10 | 2024 | 458 | 2.070 |
Why?
|
| Communicable Diseases | 8 | 2020 | 874 | 1.680 |
Why?
|
| Diagnostic Tests, Routine | 5 | 2019 | 789 | 1.490 |
Why?
|
| Laboratories | 3 | 2019 | 463 | 1.460 |
Why?
|
| Bacteriological Techniques | 5 | 2019 | 277 | 1.430 |
Why?
|
| Bacterial Infections | 7 | 2022 | 1397 | 1.400 |
Why?
|
| Reagent Strips | 2 | 2019 | 40 | 1.330 |
Why?
|
| Automation, Laboratory | 2 | 2019 | 102 | 1.220 |
Why?
|
| Respiratory Tract Infections | 9 | 2022 | 1014 | 1.210 |
Why?
|
| Vibrio Infections | 2 | 2016 | 33 | 1.050 |
Why?
|
| Vibrio parahaemolyticus | 2 | 2016 | 39 | 1.040 |
Why?
|
| Paramyxoviridae Infections | 4 | 2010 | 57 | 1.020 |
Why?
|
| Societies, Scientific | 9 | 2020 | 223 | 1.010 |
Why?
|
| Water Microbiology | 2 | 2016 | 117 | 1.000 |
Why?
|
| Anti-Bacterial Agents | 15 | 2023 | 7477 | 0.980 |
Why?
|
| Gastroenteritis | 2 | 2018 | 235 | 0.940 |
Why?
|
| Metapneumovirus | 5 | 2010 | 28 | 0.940 |
Why?
|
| Lacerations | 2 | 2016 | 150 | 0.930 |
Why?
|
| Awards and Prizes | 2 | 2019 | 365 | 0.910 |
Why?
|
| Piperacillin | 1 | 2023 | 37 | 0.900 |
Why?
|
| Wound Infection | 2 | 2016 | 243 | 0.890 |
Why?
|
| Shiga-Toxigenic Escherichia coli | 2 | 2015 | 26 | 0.850 |
Why?
|
| Cartoons as Topic | 5 | 2021 | 13 | 0.820 |
Why?
|
| Viruses | 4 | 2016 | 373 | 0.720 |
Why?
|
| Journal Impact Factor | 6 | 2016 | 157 | 0.720 |
Why?
|
| Bacteria | 5 | 2019 | 2216 | 0.700 |
Why?
|
| Public Health Administration | 2 | 2020 | 242 | 0.670 |
Why?
|
| Staphylococcus | 1 | 2020 | 146 | 0.670 |
Why?
|
| Escherichia coli Infections | 3 | 2015 | 524 | 0.650 |
Why?
|
| Serologic Tests | 2 | 2019 | 382 | 0.640 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3115 | 0.610 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 3238 | 0.610 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 3 | 2011 | 452 | 0.600 |
Why?
|
| Virus Diseases | 4 | 2016 | 724 | 0.590 |
Why?
|
| Reagent Kits, Diagnostic | 4 | 2020 | 238 | 0.570 |
Why?
|
| Marketing | 1 | 2019 | 224 | 0.570 |
Why?
|
| Foodborne Diseases | 1 | 2017 | 41 | 0.560 |
Why?
|
| Drug Resistance, Bacterial | 7 | 2022 | 1063 | 0.560 |
Why?
|
| Molecular Epidemiology | 1 | 2019 | 473 | 0.550 |
Why?
|
| Phlebotomy | 1 | 2017 | 138 | 0.530 |
Why?
|
| T-Lymphocytes, Cytotoxic | 12 | 2000 | 1801 | 0.530 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2018 | 620 | 0.520 |
Why?
|
| Communicable Disease Control | 2 | 2020 | 857 | 0.500 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2017 | 219 | 0.500 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2016 | 85 | 0.500 |
Why?
|
| Fungi | 3 | 2016 | 345 | 0.490 |
Why?
|
| Anti-Infective Agents | 2 | 2019 | 983 | 0.490 |
Why?
|
| Carrier State | 5 | 2013 | 529 | 0.480 |
Why?
|
| Metagenomics | 1 | 2018 | 474 | 0.470 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 4 | 2017 | 704 | 0.460 |
Why?
|
| Erythromycin | 2 | 2004 | 115 | 0.450 |
Why?
|
| Influenza, Human | 6 | 2011 | 1541 | 0.450 |
Why?
|
| Publications | 1 | 2016 | 195 | 0.450 |
Why?
|
| Clindamycin | 2 | 2004 | 138 | 0.440 |
Why?
|
| Publishing | 3 | 2020 | 837 | 0.430 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2022 | 4580 | 0.420 |
Why?
|
| Interleukin-2 | 8 | 2000 | 1895 | 0.410 |
Why?
|
| Humans | 106 | 2024 | 768166 | 0.400 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 3 | 2019 | 505 | 0.370 |
Why?
|
| Burkholderia Infections | 4 | 2013 | 41 | 0.360 |
Why?
|
| Staphylococcal Infections | 4 | 2012 | 1398 | 0.360 |
Why?
|
| Virology | 1 | 2011 | 76 | 0.360 |
Why?
|
| Virus Cultivation | 2 | 2009 | 88 | 0.360 |
Why?
|
| Immune System | 1 | 2016 | 799 | 0.350 |
Why?
|
| Mycoses | 1 | 2013 | 386 | 0.350 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 3 | 2002 | 897 | 0.350 |
Why?
|
| History, 21st Century | 4 | 2019 | 1573 | 0.340 |
Why?
|
| Cross Infection | 3 | 2014 | 1426 | 0.340 |
Why?
|
| Clostridium Infections | 2 | 2014 | 562 | 0.340 |
Why?
|
| Nucleic Acid Amplification Techniques | 3 | 2018 | 340 | 0.340 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 1238 | 0.320 |
Why?
|
| Antigens, Viral | 2 | 2010 | 995 | 0.320 |
Why?
|
| Cytotoxicity, Immunologic | 6 | 2000 | 1353 | 0.310 |
Why?
|
| Community-Acquired Infections | 1 | 2012 | 472 | 0.310 |
Why?
|
| Host-Pathogen Interactions | 3 | 2016 | 1469 | 0.310 |
Why?
|
| Genes, Bacterial | 4 | 2013 | 1076 | 0.290 |
Why?
|
| Peer Review, Research | 2 | 2024 | 344 | 0.290 |
Why?
|
| Cystic Fibrosis | 5 | 2022 | 1294 | 0.280 |
Why?
|
| History, 20th Century | 4 | 2019 | 2766 | 0.280 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 3671 | 0.260 |
Why?
|
| Abdominal Pain | 1 | 2012 | 1070 | 0.250 |
Why?
|
| Antibodies, Viral | 2 | 2016 | 3216 | 0.250 |
Why?
|
| Biomedical Research | 3 | 2020 | 3463 | 0.250 |
Why?
|
| Appendicitis | 1 | 2012 | 690 | 0.240 |
Why?
|
| Sensitivity and Specificity | 8 | 2020 | 14729 | 0.240 |
Why?
|
| Food Microbiology | 2 | 2017 | 74 | 0.240 |
Why?
|
| Bacteremia | 3 | 2021 | 986 | 0.230 |
Why?
|
| Education, Medical | 1 | 2016 | 1742 | 0.220 |
Why?
|
| Child | 30 | 2022 | 80917 | 0.220 |
Why?
|
| Child, Preschool | 24 | 2016 | 42669 | 0.210 |
Why?
|
| Shiga Toxin | 2 | 2015 | 36 | 0.210 |
Why?
|
| Interferon-gamma | 6 | 2013 | 3160 | 0.210 |
Why?
|
| Burkholderia | 2 | 2013 | 35 | 0.210 |
Why?
|
| Neoplasms, Experimental | 4 | 1996 | 1230 | 0.200 |
Why?
|
| Immunoassay | 3 | 2010 | 746 | 0.200 |
Why?
|
| Membrane Glycoproteins | 4 | 2000 | 3711 | 0.200 |
Why?
|
| Streptococcus agalactiae | 1 | 2004 | 337 | 0.200 |
Why?
|
| Lymphocyte Activation | 6 | 2002 | 5505 | 0.200 |
Why?
|
| Reverse Transcription | 1 | 2022 | 48 | 0.200 |
Why?
|
| Costs and Cost Analysis | 2 | 2018 | 1667 | 0.200 |
Why?
|
| Infant | 21 | 2016 | 36535 | 0.200 |
Why?
|
| Antigens, CD | 5 | 2000 | 4035 | 0.190 |
Why?
|
| Streptococcus pyogenes | 1 | 2004 | 293 | 0.190 |
Why?
|
| Laboratory Chemicals | 1 | 2021 | 2 | 0.190 |
Why?
|
| Pneumococcal Vaccines | 3 | 2010 | 414 | 0.180 |
Why?
|
| Pandemics | 4 | 2022 | 8748 | 0.180 |
Why?
|
| Coagulase | 1 | 2020 | 53 | 0.170 |
Why?
|
| Immunoglobulin Class Switching | 2 | 2002 | 289 | 0.170 |
Why?
|
| Mice, Inbred BALB C | 17 | 2002 | 6231 | 0.170 |
Why?
|
| Fusarium | 1 | 2020 | 50 | 0.170 |
Why?
|
| Vesicular stomatitis Indiana virus | 1 | 2000 | 93 | 0.170 |
Why?
|
| Chromosomes, Fungal | 1 | 2020 | 111 | 0.170 |
Why?
|
| Leadership | 2 | 2019 | 1397 | 0.160 |
Why?
|
| Interleukin-3 | 3 | 1998 | 425 | 0.160 |
Why?
|
| HLA-B7 Antigen | 1 | 1998 | 48 | 0.160 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2001 | 4415 | 0.160 |
Why?
|
| Genome, Fungal | 1 | 2020 | 203 | 0.160 |
Why?
|
| Leukopoiesis | 1 | 1998 | 54 | 0.160 |
Why?
|
| Predictive Value of Tests | 5 | 2017 | 15454 | 0.160 |
Why?
|
| Histocompatibility Antigens Class I | 6 | 1998 | 1361 | 0.160 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2023 | 1276 | 0.150 |
Why?
|
| Lactobacillus | 1 | 2019 | 212 | 0.150 |
Why?
|
| Respiratory Syncytial Viruses | 2 | 2010 | 168 | 0.150 |
Why?
|
| Larva | 1 | 2019 | 515 | 0.140 |
Why?
|
| Health Policy | 2 | 2020 | 2698 | 0.140 |
Why?
|
| Pseudomonas Infections | 1 | 2022 | 623 | 0.140 |
Why?
|
| Infant, Newborn | 12 | 2022 | 26422 | 0.140 |
Why?
|
| Stenotrophomonas maltophilia | 1 | 2017 | 18 | 0.140 |
Why?
|
| Opportunistic Infections | 1 | 2020 | 375 | 0.140 |
Why?
|
| Endoscopes, Gastrointestinal | 1 | 2016 | 45 | 0.140 |
Why?
|
| Selection, Genetic | 3 | 2017 | 877 | 0.140 |
Why?
|
| Equipment Reuse | 1 | 2016 | 45 | 0.140 |
Why?
|
| Cephalosporins | 1 | 2017 | 200 | 0.130 |
Why?
|
| Respiratory Syncytial Virus Infections | 3 | 2010 | 365 | 0.130 |
Why?
|
| Diarrhea, Infantile | 1 | 2016 | 100 | 0.130 |
Why?
|
| Genome, Bacterial | 3 | 2019 | 796 | 0.130 |
Why?
|
| Blood Specimen Collection | 1 | 2017 | 238 | 0.130 |
Why?
|
| Probiotics | 1 | 2019 | 387 | 0.130 |
Why?
|
| Lung Diseases | 2 | 2011 | 1944 | 0.120 |
Why?
|
| Equipment Contamination | 1 | 2016 | 183 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2013 | 5717 | 0.120 |
Why?
|
| Adjuvants, Immunologic | 1 | 2000 | 998 | 0.120 |
Why?
|
| Enterovirus | 2 | 2012 | 69 | 0.120 |
Why?
|
| United States | 13 | 2020 | 73039 | 0.120 |
Why?
|
| Infant Formula | 1 | 2016 | 194 | 0.120 |
Why?
|
| DNA, Bacterial | 3 | 2012 | 1478 | 0.120 |
Why?
|
| Pharynx | 2 | 2010 | 436 | 0.120 |
Why?
|
| Bacterial Typing Techniques | 1 | 2015 | 263 | 0.120 |
Why?
|
| Sarcoma, Experimental | 1 | 1994 | 117 | 0.110 |
Why?
|
| Adolescent | 16 | 2017 | 89169 | 0.110 |
Why?
|
| Reference Standards | 1 | 2017 | 1014 | 0.110 |
Why?
|
| Nasopharynx | 3 | 2012 | 420 | 0.110 |
Why?
|
| Pneumococcal Infections | 2 | 2010 | 529 | 0.110 |
Why?
|
| Prevalence | 7 | 2017 | 15869 | 0.110 |
Why?
|
| RNA, Viral | 1 | 2022 | 2872 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 1 | 2016 | 1703 | 0.110 |
Why?
|
| Streptococcal Infections | 2 | 2010 | 619 | 0.110 |
Why?
|
| Streptococcus pneumoniae | 2 | 2010 | 764 | 0.110 |
Why?
|
| Respiratory System | 1 | 2016 | 564 | 0.100 |
Why?
|
| Animals | 29 | 2019 | 169246 | 0.100 |
Why?
|
| Hand, Foot and Mouth Disease | 1 | 2012 | 25 | 0.100 |
Why?
|
| Taenia | 1 | 2012 | 17 | 0.100 |
Why?
|
| Taeniasis | 1 | 2012 | 15 | 0.100 |
Why?
|
| Diagnostic Services | 1 | 2012 | 33 | 0.100 |
Why?
|
| Molecular Typing | 1 | 2012 | 115 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 7454 | 0.100 |
Why?
|
| Animal Feed | 1 | 2012 | 105 | 0.100 |
Why?
|
| Burkholderia cepacia complex | 1 | 2012 | 24 | 0.100 |
Why?
|
| Meningitis, Viral | 1 | 2012 | 50 | 0.100 |
Why?
|
| Feces | 3 | 2016 | 1511 | 0.100 |
Why?
|
| Female | 32 | 2020 | 397192 | 0.100 |
Why?
|
| Reference Values | 1 | 2019 | 4938 | 0.100 |
Why?
|
| Research | 1 | 2020 | 1979 | 0.100 |
Why?
|
| Enterotoxins | 1 | 2013 | 366 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 3 | 1994 | 1996 | 0.100 |
Why?
|
| Enterovirus Infections | 1 | 2012 | 74 | 0.100 |
Why?
|
| Diarrhea | 2 | 2019 | 1320 | 0.090 |
Why?
|
| Streptococcus milleri Group | 1 | 2010 | 6 | 0.090 |
Why?
|
| Mandatory Reporting | 1 | 2012 | 123 | 0.090 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2012 | 412 | 0.090 |
Why?
|
| Lung Abscess | 1 | 2010 | 39 | 0.090 |
Why?
|
| Hospitals | 1 | 2004 | 3886 | 0.090 |
Why?
|
| Latent Tuberculosis | 1 | 2013 | 224 | 0.090 |
Why?
|
| Sulfamethoxazole | 1 | 2010 | 50 | 0.090 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2010 | 28 | 0.090 |
Why?
|
| Trimethoprim | 1 | 2010 | 79 | 0.090 |
Why?
|
| Bacterial Proteins | 3 | 2013 | 3840 | 0.090 |
Why?
|
| Lyme Disease | 1 | 2016 | 630 | 0.090 |
Why?
|
| Antibodies, Bacterial | 2 | 2016 | 1479 | 0.090 |
Why?
|
| Fimbriae Proteins | 1 | 2010 | 133 | 0.080 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1995 | 977 | 0.080 |
Why?
|
| Phylogeny | 4 | 2020 | 2843 | 0.080 |
Why?
|
| Boston | 5 | 2012 | 9374 | 0.080 |
Why?
|
| Inappropriate Prescribing | 1 | 2012 | 212 | 0.080 |
Why?
|
| Terminology as Topic | 1 | 2016 | 1542 | 0.080 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2016 | 1354 | 0.080 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2012 | 582 | 0.080 |
Why?
|
| Male | 30 | 2020 | 364719 | 0.080 |
Why?
|
| Culture Media | 1 | 2010 | 898 | 0.080 |
Why?
|
| Mice | 24 | 2012 | 82029 | 0.080 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2013 | 591 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2000 | 4648 | 0.080 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2012 | 1027 | 0.080 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1992 | 1441 | 0.070 |
Why?
|
| Killer Cells, Natural | 2 | 1995 | 2211 | 0.070 |
Why?
|
| Breast Feeding | 1 | 2016 | 1363 | 0.070 |
Why?
|
| Bacterial Toxins | 1 | 2013 | 922 | 0.070 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 4 | 1994 | 1105 | 0.070 |
Why?
|
| Pleural Effusion | 1 | 2010 | 344 | 0.070 |
Why?
|
| Th2 Cells | 3 | 2002 | 1078 | 0.070 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2009 | 149 | 0.070 |
Why?
|
| Transfection | 8 | 1996 | 5755 | 0.070 |
Why?
|
| Bronchiolitis, Viral | 1 | 2008 | 82 | 0.070 |
Why?
|
| Fimbriae, Bacterial | 1 | 2007 | 138 | 0.070 |
Why?
|
| Mass Screening | 2 | 2020 | 5458 | 0.070 |
Why?
|
| Cytokines | 4 | 2002 | 7453 | 0.070 |
Why?
|
| Meningococcal Vaccines | 1 | 2007 | 96 | 0.070 |
Why?
|
| Nose | 1 | 2010 | 522 | 0.070 |
Why?
|
| Rhinovirus | 1 | 2008 | 209 | 0.070 |
Why?
|
| Disease Outbreaks | 2 | 2013 | 1761 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 2 | 2013 | 6082 | 0.070 |
Why?
|
| Th1 Cells | 2 | 2002 | 1042 | 0.070 |
Why?
|
| Immunoconjugates | 3 | 1999 | 975 | 0.070 |
Why?
|
| High-Throughput Screening Assays | 1 | 2012 | 942 | 0.060 |
Why?
|
| Bronchiolitis | 1 | 2012 | 492 | 0.060 |
Why?
|
| Pediatrics | 3 | 2020 | 3629 | 0.060 |
Why?
|
| Mice, Knockout | 7 | 2002 | 14488 | 0.060 |
Why?
|
| Dogs | 1 | 2009 | 3845 | 0.060 |
Why?
|
| Lung | 3 | 2017 | 10099 | 0.060 |
Why?
|
| Lincosamides | 1 | 2004 | 5 | 0.060 |
Why?
|
| Pneumonia | 1 | 2016 | 2163 | 0.060 |
Why?
|
| Immunocompromised Host | 1 | 2010 | 863 | 0.060 |
Why?
|
| Paramyxoviridae | 1 | 2004 | 9 | 0.060 |
Why?
|
| Mice, Inbred Strains | 2 | 2000 | 1765 | 0.060 |
Why?
|
| Agar | 1 | 2004 | 51 | 0.060 |
Why?
|
| Influenza A virus | 1 | 2008 | 460 | 0.060 |
Why?
|
| Antigens, Bacterial | 2 | 2013 | 1150 | 0.060 |
Why?
|
| Seasons | 3 | 2006 | 1524 | 0.060 |
Why?
|
| Haptens | 2 | 2001 | 163 | 0.060 |
Why?
|
| Retrospective Studies | 9 | 2021 | 81762 | 0.060 |
Why?
|
| Urinary Tract Infections | 1 | 2010 | 804 | 0.060 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 1673 | 0.050 |
Why?
|
| Indians, North American | 1 | 2007 | 354 | 0.050 |
Why?
|
| Lymphocyte Culture Test, Mixed | 2 | 2000 | 510 | 0.050 |
Why?
|
| Evolution, Molecular | 1 | 2011 | 1896 | 0.050 |
Why?
|
| Radiography, Thoracic | 1 | 2009 | 1321 | 0.050 |
Why?
|
| Genetic Variation | 2 | 2019 | 6611 | 0.050 |
Why?
|
| Inclusion Bodies | 1 | 2004 | 278 | 0.050 |
Why?
|
| Macrolides | 1 | 2004 | 204 | 0.050 |
Why?
|
| Time Factors | 3 | 2021 | 40218 | 0.050 |
Why?
|
| Massachusetts | 6 | 2016 | 8890 | 0.050 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2004 | 687 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 5 | 1998 | 6124 | 0.050 |
Why?
|
| Biological Products | 1 | 2012 | 948 | 0.050 |
Why?
|
| Hospitalization | 4 | 2012 | 10840 | 0.050 |
Why?
|
| Staphylococcus aureus | 1 | 2010 | 1430 | 0.050 |
Why?
|
| Meningitis, Bacterial | 1 | 2004 | 225 | 0.050 |
Why?
|
| Diffusion | 1 | 2004 | 815 | 0.050 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2004 | 760 | 0.050 |
Why?
|
| Graft Rejection | 2 | 1999 | 4492 | 0.050 |
Why?
|
| Antigens, Differentiation | 3 | 1999 | 921 | 0.050 |
Why?
|
| Emergency Service, Hospital | 4 | 2009 | 7951 | 0.050 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2004 | 404 | 0.050 |
Why?
|
| Methyltransferases | 1 | 2004 | 373 | 0.050 |
Why?
|
| Chi-Square Distribution | 3 | 2013 | 3436 | 0.040 |
Why?
|
| Laboratory Personnel | 1 | 2020 | 19 | 0.040 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2001 | 158 | 0.040 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2000 | 317 | 0.040 |
Why?
|
| Cell Line | 3 | 2009 | 15597 | 0.040 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2002 | 137 | 0.040 |
Why?
|
| Health Personnel | 1 | 2013 | 3385 | 0.040 |
Why?
|
| Office Visits | 1 | 2004 | 595 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 2000 | 1142 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 2022 | 830 | 0.040 |
Why?
|
| CD40 Ligand | 1 | 2001 | 528 | 0.040 |
Why?
|
| Health Services | 1 | 2004 | 755 | 0.040 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2013 | 2442 | 0.040 |
Why?
|
| Germinal Center | 1 | 2001 | 380 | 0.040 |
Why?
|
| Gene Targeting | 1 | 2001 | 841 | 0.040 |
Why?
|
| Immunoglobulins | 1 | 2000 | 855 | 0.040 |
Why?
|
| Immunity, Cellular | 2 | 1993 | 1561 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 1999 | 587 | 0.040 |
Why?
|
| Gene Expression Regulation, Fungal | 1 | 2020 | 497 | 0.030 |
Why?
|
| Incidence | 2 | 2013 | 21538 | 0.030 |
Why?
|
| Hospitals, Pediatric | 2 | 2021 | 1876 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2010 | 13014 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2007 | 4786 | 0.030 |
Why?
|
| Prospective Studies | 7 | 2022 | 54926 | 0.030 |
Why?
|
| Half-Life | 1 | 2017 | 651 | 0.030 |
Why?
|
| T-Lymphocytes | 3 | 2013 | 10266 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 15948 | 0.030 |
Why?
|
| Colony Count, Microbial | 1 | 2016 | 328 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2001 | 1393 | 0.030 |
Why?
|
| Signal Transduction | 2 | 1999 | 23645 | 0.030 |
Why?
|
| Enteral Nutrition | 1 | 2022 | 802 | 0.030 |
Why?
|
| Intestine, Small | 1 | 2022 | 1217 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 2012 | 2357 | 0.030 |
Why?
|
| Hospital Units | 1 | 2016 | 142 | 0.030 |
Why?
|
| Fungal Proteins | 1 | 2020 | 906 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2006 | 2596 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 1998 | 960 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2012 | 41754 | 0.030 |
Why?
|
| Disinfection | 1 | 2016 | 207 | 0.030 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 3415 | 0.030 |
Why?
|
| Borrelia burgdorferi | 1 | 2016 | 183 | 0.030 |
Why?
|
| Zidovudine | 1 | 2016 | 625 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 3055 | 0.030 |
Why?
|
| Spleen | 1 | 2000 | 2295 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 996 | 0.030 |
Why?
|
| Ligands | 1 | 2000 | 3284 | 0.030 |
Why?
|
| Neoplasm Transplantation | 2 | 1994 | 2014 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2000 | 2204 | 0.030 |
Why?
|
| Intensive Care Units | 2 | 2019 | 3800 | 0.030 |
Why?
|
| Botswana | 1 | 2016 | 1058 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2000 | 11669 | 0.030 |
Why?
|
| Prognosis | 2 | 2012 | 30010 | 0.030 |
Why?
|
| Blood Bactericidal Activity | 1 | 2012 | 124 | 0.020 |
Why?
|
| Young Adult | 3 | 2013 | 60066 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2020 | 3956 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1995 | 892 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 3740 | 0.020 |
Why?
|
| Clone Cells | 2 | 1992 | 1670 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2000 | 4146 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2017 | 964 | 0.020 |
Why?
|
| Colorimetry | 1 | 2012 | 151 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 17622 | 0.020 |
Why?
|
| Adaptation, Biological | 1 | 2011 | 147 | 0.020 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 1993 | 506 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2004 | 4937 | 0.020 |
Why?
|
| Carcinoma | 2 | 1993 | 2332 | 0.020 |
Why?
|
| Eosinophils | 1 | 1995 | 952 | 0.020 |
Why?
|
| Interleukins | 1 | 1995 | 796 | 0.020 |
Why?
|
| Bodily Secretions | 1 | 2010 | 28 | 0.020 |
Why?
|
| Time | 1 | 2012 | 552 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 2202 | 0.020 |
Why?
|
| Genes, MHC Class I | 1 | 1991 | 235 | 0.020 |
Why?
|
| Ampicillin | 1 | 2010 | 137 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 7 | 1999 | 22379 | 0.020 |
Why?
|
| Mutation | 3 | 2022 | 30238 | 0.020 |
Why?
|
| Adult | 7 | 2017 | 223646 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2020 | 5403 | 0.020 |
Why?
|
| Ciprofloxacin | 1 | 2011 | 313 | 0.020 |
Why?
|
| HIV Infections | 1 | 2016 | 17569 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 2 | 1999 | 1815 | 0.020 |
Why?
|
| Risk Factors | 5 | 2010 | 74944 | 0.020 |
Why?
|
| Operon | 1 | 2010 | 371 | 0.020 |
Why?
|
| Lung Neoplasms | 5 | 1996 | 13586 | 0.020 |
Why?
|
| Cross-Sectional Studies | 3 | 2016 | 26379 | 0.020 |
Why?
|
| Graft Survival | 1 | 1999 | 3887 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2020 | 1885 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2011 | 994 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 1999 | 2747 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 1995 | 1377 | 0.020 |
Why?
|
| Cost of Illness | 2 | 2009 | 1951 | 0.020 |
Why?
|
| Utilization Review | 1 | 2009 | 381 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2020 | 13421 | 0.020 |
Why?
|
| Virulence Factors | 1 | 2011 | 502 | 0.020 |
Why?
|
| Cell Separation | 1 | 1993 | 1728 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2000 | 9561 | 0.020 |
Why?
|
| Pituitary Gland, Anterior | 1 | 1987 | 142 | 0.020 |
Why?
|
| Ecosystem | 1 | 2012 | 494 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 1995 | 1997 | 0.020 |
Why?
|
| Stem Cells | 1 | 2000 | 3537 | 0.020 |
Why?
|
| Tachykinins | 1 | 1987 | 77 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2001 | 4793 | 0.020 |
Why?
|
| Ovalbumin | 2 | 1999 | 677 | 0.020 |
Why?
|
| Nasal Cavity | 1 | 2009 | 310 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 20760 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2012 | 2486 | 0.020 |
Why?
|
| Occupational Health | 1 | 2013 | 812 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2004 | 7876 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2013 | 1312 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2019 | 16045 | 0.020 |
Why?
|
| Serotyping | 1 | 2007 | 331 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 1996 | 2463 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 2923 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2012 | 1530 | 0.020 |
Why?
|
| Epidemics | 1 | 2011 | 517 | 0.020 |
Why?
|
| Proteins | 1 | 2000 | 6009 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 1999 | 3301 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 10760 | 0.020 |
Why?
|
| Latex Fixation Tests | 1 | 2004 | 29 | 0.010 |
Why?
|
| Thyroid Hormones | 1 | 1987 | 407 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 1998 | 3114 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 2862 | 0.010 |
Why?
|
| Internet | 1 | 2016 | 3110 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 2219 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2010 | 2089 | 0.010 |
Why?
|
| Genomics | 1 | 2019 | 5926 | 0.010 |
Why?
|
| Protein Precursors | 1 | 1987 | 1134 | 0.010 |
Why?
|
| Health Resources | 1 | 2009 | 950 | 0.010 |
Why?
|
| Virulence | 1 | 2007 | 1297 | 0.010 |
Why?
|
| Emergency Medicine | 1 | 2012 | 1223 | 0.010 |
Why?
|
| Leishmania mexicana | 1 | 2002 | 33 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2009 | 2732 | 0.010 |
Why?
|
| Neuropeptides | 1 | 1987 | 951 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2010 | 6229 | 0.010 |
Why?
|
| Cerebrospinal Fluid | 1 | 2004 | 540 | 0.010 |
Why?
|
| Treatment Outcome | 3 | 2017 | 65371 | 0.010 |
Why?
|
| Health Maintenance Organizations | 1 | 2004 | 657 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 2005 | 1695 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 2016 | 4573 | 0.010 |
Why?
|
| Antigens, T-Independent | 1 | 1999 | 20 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 6316 | 0.010 |
Why?
|
| OX40 Ligand | 1 | 1999 | 57 | 0.010 |
Why?
|
| Tumor Necrosis Factors | 1 | 1999 | 109 | 0.010 |
Why?
|
| Immunotherapy | 2 | 2012 | 4755 | 0.010 |
Why?
|
| Syndrome | 1 | 2006 | 3272 | 0.010 |
Why?
|
| Dermatitis, Contact | 1 | 1999 | 134 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1999 | 491 | 0.010 |
Why?
|
| Length of Stay | 1 | 2012 | 6498 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1999 | 1084 | 0.010 |
Why?
|
| International Classification of Diseases | 1 | 2004 | 937 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 2012 | 18349 | 0.010 |
Why?
|
| Contrast Media | 1 | 2010 | 5330 | 0.010 |
Why?
|
| Health Expenditures | 1 | 2009 | 2389 | 0.010 |
Why?
|
| Mast-Cell Sarcoma | 1 | 1996 | 46 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2006 | 6340 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2009 | 12077 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 1996 | 624 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 1998 | 6514 | 0.010 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1999 | 528 | 0.010 |
Why?
|
| Comorbidity | 1 | 2009 | 10590 | 0.010 |
Why?
|
| Flow Cytometry | 2 | 1999 | 5902 | 0.010 |
Why?
|
| Vaccination | 1 | 2007 | 3437 | 0.010 |
Why?
|
| Logistic Models | 1 | 2009 | 13290 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2002 | 2937 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 1993 | 174 | 0.010 |
Why?
|
| Thymidine Kinase | 1 | 1993 | 286 | 0.010 |
Why?
|
| Ganciclovir | 1 | 1993 | 256 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2009 | 4746 | 0.010 |
Why?
|
| Age Factors | 1 | 2009 | 18412 | 0.010 |
Why?
|
| Survival Rate | 1 | 2005 | 12840 | 0.010 |
Why?
|
| Cell Division | 1 | 1999 | 4473 | 0.010 |
Why?
|
| H-2 Antigens | 1 | 1991 | 359 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1999 | 4833 | 0.010 |
Why?
|
| Magnetics | 1 | 1993 | 597 | 0.010 |
Why?
|
| Antibodies | 1 | 1999 | 2421 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 1998 | 2414 | 0.010 |
Why?
|
| Decision Making | 1 | 2004 | 3953 | 0.010 |
Why?
|
| Microspheres | 1 | 1993 | 788 | 0.010 |
Why?
|
| Dimethyl Sulfoxide | 1 | 1991 | 250 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1993 | 749 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2004 | 7852 | 0.010 |
Why?
|
| Simplexvirus | 1 | 1993 | 805 | 0.010 |
Why?
|
| Epitopes | 1 | 1996 | 2528 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 1987 | 11928 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2006 | 14783 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 1993 | 1156 | 0.010 |
Why?
|
| Neurokinin A | 1 | 1987 | 32 | 0.000 |
Why?
|
| Immunization | 1 | 1991 | 1219 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1987 | 2087 | 0.000 |
Why?
|
| RNA, Messenger | 2 | 1993 | 12800 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 59629 | 0.000 |
Why?
|
| Algorithms | 1 | 2004 | 14164 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1998 | 19015 | 0.000 |
Why?
|
| Oxidation-Reduction | 1 | 1987 | 2227 | 0.000 |
Why?
|
| Phenotype | 1 | 1999 | 16726 | 0.000 |
Why?
|
| Gene Expression | 1 | 1993 | 7598 | 0.000 |
Why?
|
| Neoplasm Metastasis | 1 | 1991 | 4912 | 0.000 |
Why?
|
| Aged | 1 | 2010 | 171504 | 0.000 |
Why?
|
| Middle Aged | 1 | 2010 | 223492 | 0.000 |
Why?
|
| Models, Biological | 1 | 1991 | 9495 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 1991 | 9263 | 0.000 |
Why?
|
| Prostatic Neoplasms | 1 | 1996 | 11101 | 0.000 |
Why?
|
| Rats | 1 | 1987 | 23760 | 0.000 |
Why?
|